Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.3%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) shares were down 3.3% during trading on Tuesday . The company traded as low as $9.64 and last traded at $9.67. Approximately 22,270 shares were traded during trading, a decline of 94% from the average daily volume of 348,044 shares. The stock had previously closed at $10.00.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Centessa Pharmaceuticals Price Performance

The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The company has a market cap of $895.77 million, a PE ratio of -5.69 and a beta of 1.38. The firm has a 50 day moving average of $10.90 and a two-hundred day moving average of $8.51.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The company had revenue of $6.85 million during the quarter. Research analysts predict that Centessa Pharmaceuticals plc will post -1.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, SVP Harris Rotman sold 4,267 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the sale, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Harris Rotman sold 4,267 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total value of $34,562.70. Following the transaction, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the transaction, the insider now owns 71,525 shares in the company, valued at $849,717. The disclosure for this sale can be found here. Company insiders own 11.54% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after purchasing an additional 5,037 shares during the period. Quarry LP bought a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $48,000. Jump Financial LLC bought a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $114,000. Trexquant Investment LP bought a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $114,000. Finally, Rathbones Group PLC bought a new stake in Centessa Pharmaceuticals during the third quarter valued at about $203,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.